慢性鼻窦炎与内耳功能障碍

注册号:

Registration number:

ChiCTR2100046559 

最近更新日期:

Date of Last Refreshed on:

2021-12-29 21:28:05 

注册时间:

Date of Registration:

2021-05-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

慢性鼻窦炎与内耳功能障碍

Public title:

Study on chronic rhinosinusitis and inner ear dysfunction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

慢性鼻窦炎与内耳功能障碍及其相关因素分析

Scientific title:

Chronic rhinosinusitis and inner ear dysfunction and its related factor

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈玲 

研究负责人:

林熹 

Applicant:

Chen Ling 

Study leader:

Lin Xi 

申请注册联系人电话:

Applicant telephone:

+86 13666978785

研究负责人电话:

Study leader's
telephone:

+86 13338251926

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

chenling2370@163.com

研究负责人电子邮件:

Study leader's E-mail:

linxi86@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市台江区交通路88号

研究负责人通讯地址:

福建省福州市台江区交通路88号

Applicant address:

88 Jiaotong Road, Taijiang District, Fuzhou, Fujian

Study leader's address:

88 Jiaotong Road, Taijiang District, Fuzhou, Fujian

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Fujian Medical University

研究负责人所在单位:

福建医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Fujian Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

闽医大附一伦理医研【2021】133号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建医科大学附属第一医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Fujian Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-04-07 00:00:00

伦理委员会联系人:

张秀秀

Contact Name of the ethic committee:

Zhang Xiuxiu

伦理委员会联系地址:

福建省福州市茶中路20号

Contact Address of the ethic committee:

20 Chazhong Road, Fuzhou, Fujian

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 591 87981028

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

福建医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Fujian Medical University

研究实施负责(组长)单位地址:

福建省福州市茶中路20号

Primary sponsor's address:

20 Chazhong Road, Fuzhou, Fujian

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

福州

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建医科大学附属第一医院

具体地址:

茶中路20号

Institution
hospital:

The First Affiliated Hospital of Fujian Medical University

Address:

20 Chazhong Road

经费或物资来源:

Source(s) of funding:

N/A

研究疾病:

慢性鼻窦炎与内耳功能障碍  

Target disease:

Chronic rhinosinusitis and inner ear dysfunction

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

本研究将通过多种手段探究慢性鼻-鼻窦炎患者是否存在感音神经性听力下降、眩晕、平衡功能障碍等内耳功能障碍,并寻找他可能发生的机制,为慢性鼻-鼻窦炎引起内耳功能障碍提供初步的研究线索。  

Objectives of Study:

This study will explore whether there are sensorineural hearing loss, vertigo, balance dysfunction and other inner ear dysfunction in patients with chronic rhinosinusitis through a variety of means, and find out the possible mechanism, so as to provide preliminary research clues for inner ear dysfunction caused by chronic rhinosinusitis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.年龄>60岁;
2.既往有耳部疾病(中耳炎、耳部外伤、鼓膜穿孔、耳部肿瘤等);
3.明确的耳毒性药物接触式(氨基甙类抗生素:链霉素、卡那霉素、新霉素、庆大霉素等,抗癌药物:长春新碱、顺氯氨铂,大环内酯类抗生素:红霉素等,水杨酸类解热镇痛药,抗疟药等);
4.有长期持续噪音暴露史(>85dB);
5.患有某些可能影响听力的全身系统性疾病(高血压、糖尿病、睡眠呼吸暂停综合征、自身免疫性疾病、甲状腺疾病、支气管哮喘、颈椎病、肾病、贫血等)
6.患有某些可能影响听力的感染性疾病:(腮腺炎、麻疹、风疹、流行性脑脊髓膜炎、猩红热、白喉、伤寒、带状疱疹、梅毒等);
7.特殊职业工作者:潜水员、飞行员、隧道作业者;
8.妊娠期;
9.既往有癫痫病史者。

Exclusion criteria:

1. Aged > 60 years;
2. Past ear diseases (otitis media, ear trauma, tympanic membrane perforation, ear tumors, etc.);
3. Clear ototoxic drug contact type (aminoglycoside antibiotics: streptomycin, kanamycin, neomycin, gentamicin, etc., anticancer drugs: vincristine, cisplatin, macrocyclic Ester antibiotics: erythromycin, etc., salicylic acid antipyretic analgesics, antimalarials, etc.);
4. Have long-term continuous noise exposure history (>85dB);
5. Suffer from certain systemic diseases that may affect hearing (hypertension, diabetes, sleep apnea syndrome, autoimmune disease, thyroid disease, bronchial asthma, cervical spondylopathy, kidney disease, anemia, etc.)
6. Suffering from certain infectious diseases that may affect hearing: (mumps, measles, rubella, meningitis, scarlet fever, diphtheria, typhoid fever, shingles, syphilis, etc.);
7. Special occupation workers: divers, pilots, tunnel operators;
8. During pregnancy;
9. Those who have a history of epilepsy.

研究实施时间:

Study execute time:

From 2021-05-20 00:00:00 To 2024-05-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-05-20 00:00:00 To 2024-05-20 00:00:00

干预措施:

Interventions:

组别:

期间住院的慢性鼻-鼻窦炎患者组

样本量:

100

Group:

Chronic rhinosinusitis patients who were hospitalized during the period

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

组别:

鼻中隔偏曲患者组

样本量:

50

Group:

Patients with deviated nasal septum

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Fujian Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

听力学检测

指标类型:

主要指标

Outcome:

audiometry test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

鼻腔黏膜

Sample Name:

blood

Tissue:

Nasal mucosa

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 59 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年12月;ResMan; http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

December 2022, ResMan;http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-05-21 21:29:19